Skip to main content

Table 3 Multivariate analyses of significant factors for various endpoints in the 749 patients with NPC

From: Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy

Variable

Local failure

Regional failure

Distant failure

Disease failure

Death (any cause)

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

T stage (T2, T3, and T4 vs. T1)

1.956 (1.371–2.790)

<0.001

1.243 (0.809–1.912)

0.321

1.556 (1.282–1.888)

<0.001

1.589 (1.363–1.853)

<0.001

1.583 (1.328–1.886)

<0.001

N stage (N1, N2, and N3 vs. N0)

1.233 (0.833–1.723)

0.218

1.416 (0.928–2.160)

0.106

1.741 (1.485–2.041)

<0.001

1.617 (1.415–1.847)

<0.001

1.690 (1.455–1.964)

<0.001

Age (>50 vs. ≤50 years)

1.011 (0.490–2.086)

0.976

1.005 (0.365–2.769)

0.992

1.530 (1.037–2.256)

0.032

1.896 (1.403–2.561)

<0.001

2.482 (1.770–3.482)

<0.001

Sex (female vs. male)

0.826 (0.378–1.802)

0.631

0.797 (0.266–2.386)

0.685

1.066 (0.689–1.649)

0.776

1.017 (0.713–1.450)

0.926

0.900 (0.587–1.379)

0.627

Histology (type II/III vs. type I)

1.930E4 (0.000–6.656E258)

0.974

2.104E4 (0.000–)

0.981

2.313E4 (0.000–4.202E155)

0.955

1.397 (0.194–10.043)

0.739

1.037 (0.144–7.480)

0.971

Chemotherapy (CCRT, induction with CCRT, and CCRT with adjuvant vs. none)

0.921 (0.705–1.202)

0.544

0.920 (0.629–1.345)

0.666

1.002 (0.870–1.155)

0.973

0.947 (0.840–1.068)

0.375

0.969 (0.847–1.108)

0.644

  1. HR hazard ratio, CI confidence interval, CCRT concurrent chemoradiotherapy